Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New OA Cell Therapy On Horizon As JointStem Study Succeeds

Executive Summary

A novel stem cell therapy for osteoarthritis developed by South Korean biotech Nature Cell is set to debut in the country this year, providing an alternative for advanced patients who have limited treatment options.

You may also be interested in...

Nature Cell Mired In Uncertainty as CEO Arrested For Alleged Stock Price Manipulation

The Korean biotechs CEO and several other executives alleged involvement in stock price manipulation using false and exaggerated information on a pipeline stem cell therapy has damaged the credibility of its R&D efforts and shocked the domestic industry, although their fate remains to be determined after court trials.    

Kolon/Mitsubishi Gene Therapy Pact Paves Way For More Global Deals?

In a rare large gene therapy deal, South Korea’s Kolon is making inroads into the Japanese market through Invossa, its genetically modified allogeneic cell therapy for osteoarthritis. The agreement with Mitsubishi Tanabe could pave the way for more global licensing agreements in a growing segment.

K-Stemcell’s Arthritis Cell Therapy Set For Phase III In Korea

In another positive sign for South Korea’s stem cell space, one of the government’s priorities in the biotech sector, K-Stemcell will begin late-stage clinical trials with JOINTSTEM, an autologus adipose-derived stem cell therapy for degenerative arthritis, with a goal of commercialization in 2018.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts